CEO
Stephen Isaacs
Employees
231
Industry
Pharmaceutical Preparation Manufacturing
chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from richadhand@benzinga.com
August 08, 2023 | 12:41 pm
Portfolio Pulse from Benzinga Insights
August 01, 2023 | 12:20 pm
Portfolio Pulse from richadhand@benzinga.com
August 01, 2023 | 10:29 am
Portfolio Pulse from Benzinga Newsdesk
July 28, 2023 | 12:03 pm
Portfolio Pulse from richadhand@benzinga.com
June 21, 2023 | 12:28 pm
Portfolio Pulse from richadhand@benzinga.com
June 14, 2023 | 1:19 pm
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 11:25 am
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 10:16 am
Portfolio Pulse from richadhand@benzinga.com
June 13, 2023 | 10:12 am
Portfolio Pulse from Benzinga Newsdesk
June 12, 2023 | 8:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.